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Treatment of elderly patients with aggressive non-Hodgkin lymphoma (NHL) remains a true challenge because of poor tolerance to 
standard-dose chemotherapy.1 Amifostine is a selec-
tive cytoprotector that acts as a scavenger of free radi-
cals and has a protecting activity over normal tissues.2 
Clinical trials evaluating amifostine in combination 
with chemotherapy in solid tumors have shown a re-
duction in chemotherapy-associated toxicity without 
modification of antineoplastic activity.3,4 The same re-
sult was also observed in a previous single-arm trial 
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BaCkgRounD anD oBjECtIvEs: We report the 8-year follow-up of 34 patients aged ≥ 69 years old with NHL 
included in a phase iib open-label randomized parallel groups study to evaluate the effectiveness of amifostine 
in preventing the toxicity of cyclophosphamide, doxorubicin, vincristine and prednisone (ChoP regime) .
patIEnts anD MEthoDs: Patients were randomized to receive classical ChoP (cyclophosphamide 750 mg/
m2, doxorubicin 50 mg/m2, vincristine 1.4 mg/m2 [maximum 2 mg] on day 1 and prednisone 100 mg/day for 5 
days) or ChoP plus amifostine (6 cycles of amifostine 910 mg/m2 on day 1). Efficacy (time to progression, ttP; 
disease-free survival, Dfs; overall survival, os) and toxicity endpoints were evaluated. 
REsuLts: thirty-four patients were randomized to a-ChoP (n=18) or ChoP (n=16). Patients with a-ChoP vs 
ChoP had significantly lower toxicity; neutropenia grade 4 ocurred in 13/92 (13%) vs 23/85 (27%, P=0.007) 
cycles, febrile neutropenia in 3/92 a-ChoP (3%) vs 8/85 (10%, P=.056) ChoP cycles, hospitalization for 
toxicity in 4/92 (4%) a-ChoP vs 11/85 (13%, P=.05) ChoP cycles. median hospitalization stay for toxicity 
was 5 days with a-ChoP vs 8 days with ChoP (P=.05). there were no significant differences at 8 years in ttP 
(a-ChoP, 48.9% vs ChoP, 36.3%; P=.65), Dfs (a-ChoP, 72.9% vs ChoP 55.6%; P=.50) and os (a-ChoP, 
44.3% vs ChoP, 54.4%). there was no long-term toxicity of clinical interest. the only prognostic factor identi-
fied to 8 years was the international Prognostic index (iPi low/low intermediate risk vs high intermediate/high 
risk; hr=2.98; Ci 95%:1.01-8.77; P=.048). 
ConCLusIon: these results show that amifostine can be added to the standard ChoP treatment schedule with 
less acute toxicity and without influencing the outcome.
of amifostine plus CHOP in elderly patients with ag-
gressive NHL.5 We evaluated the long-term outcome 
of the efficacy of amifostine in preventing toxicity to 
the CHOP regime in elderly patients with NHL. 
patIEnts anD MEthoDs
This was a randomized (1:1 ratio), parallel group, 
phase IIb trial to evaluate the effectiveness of amifos-
tine in preventing chemotoxicity to CHOP in elderly 
NHL patients that was carried out in two hospitals 
in Lima, Perú (Instituto Nacional de Enfermedades 
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Neoplásicas and Hospital Edgardo Rebagliatti 
Martins). Accrual was from September 2000 to 
October 2001. CHOP (cyclophosphamide 750 mg/
m2, doxorubicin 50 mg/m2, vincristine 1.4 mg/m2 
[maximum 2 mg] on day 1 and prednisone 100 mg/
day for 5 days) was given in 6 cycles of 3 weeks each. 
Amifostine (910 mg/m2) was given in 6 cycles on day 
1 (added to normal saline to a total volume of 100 
mL, administrated intravenously 15 minutes before 
chemotherapy)
Inclusion criteria were age ≥69 years old, ECOG 
performance status 0-1, aggressive NHL of the follow-
ing types according to the WHO classification: diffuse 
large B cell lymphoma, non-specific peripheral T-cell 
lymphoma, anaplastic T-cell lymphoma, grade II-III 
follicular lymphoma and mantle cell lymphoma (not 
blastoid), adequate bone marrow reserve (absolute 
neutrophil count ≥1.5×109/L, platelets ≥100×109/L), 
normal renal and hepatic function, and left ventricle 
ejection fraction greater than 50%. Patients taking 
chronic corticosteroid treatment discontinued it at 
least one week before inclusion. Exclusion criteria 
include previous chemotherapy, radiation therapy or 
modifiers of biological response, encephalic or men-
ingeal infiltration by lymphoma, HIV infection, con-
ditions that require continuous treatment between 
courses of chemotherapy, history of cardiac disease, 
active infections or illnesses that precluded the use 
of chemotherapy, concurrent malignancy or a history 
within 5 years (excluding non-melanoma skin cancer 
and early cervical uterine cancer treated for cure). 
The trial was designed to detect a difference of 20% 
in reduction, using amifostine, of grade 4 neutropenia 
events in cycles of chemotherapy, considering toxicity 
occurs in 43% of cycles in elderly patients with aggres-
sive lymphoma treated with CHOP.6 With a P=.05 
and b=0.20, 83 cycles per group were needed (an es-
timated of 16 patients per arm). Toxicity was assessed 
according to CTCAE v2.0. Survival was estimated 
with the Kaplan-Meier method and the differences 
between groups were determined by the log rank test. 
Endpoints included hematological and biochemical 
toxicities and survival. Disease-free survival (DFS), 
time-to-progression (TTP) and overall survival (OS) 
were calculated by the Kaplan-Meier method and the 
log rank or Breslow (when appropriate) tests were 
used as methods of statistical inference between the 
two treatment groups. This study was conducted in 
accordance with the principles of the Declaration of 
Helsinki, Good Clinical Practice, and the current na-
tional rules for conducting clinical studies. The proto-
col was approved by the local hospital ethics commit-
tee (trial registration number INEN 00-18), and all 
patients signed an informed consent. 
REsuLts
Thirty-four patients were randomized, 18 to the 
A-CHOP arm and 16 to the CHOP arm. Although 
the A-CHOP arm had stages III-IV cases (56% vs 
32%, without statistical significance), the International 
Prognostic Index was similar in both arms. Other char-
acteristics were balanced (Table 1).
CHOP administration
Eleven of the 18 (61%) A-CHOP patients and 12/16 
(75%) CHOP patients completed six cycles of chemo-
therapy (P=.619). Five completed fewer than 4 cycles 
due to withdrawal of consent (one patient), disease pro-
gression (one patient) and toxicity (three patients: one 
A-CHOP and two CHOP). A total of 177 cycles were 
administered (92 in A-CHOP and 85 in CHOP), with 
a median of 6 cycles in both arms. Total chemotherapy 
dose (cumulative dose of cyclophosphamide or doxoru-
bicin per square meter) was similar in both arms; how-
ever, the median treatment duration at the sixth cycle 
was significantly shorter in the A-CHOP arm (17.7 
vs 19.9 weeks; P=.01); similarly, the median of relative 
dose intensity (RDI) at sixth cycle was higher in the 
A-CHOP arm (82% vs 72%, P=.03) (Table 2). 
Efficacy
The overall response rate was 88% in A-CHOP patients 
(16/18) and 82% in CHOP patients 13/16; P=.2921 
(Table 1). Seventeen A-CHOP and 15 CHOP patients 
finished treatment and were assessable. Response rates 
were 78.5% (60% complete responses) for A-CHOP 
and 81.1% (72% complete responses) for CHOP with-
out statistical difference.
With a median of follow-up of 8.5 years, the median 
OS was 8.5 years for A-CHOP vs 8.7 for the CHOP 
arm (P=.496). A-CHOP was superior, but without sig-
nificance in 8-year DFS (72.9% vs 55.6%; P=.50), and 
PFS (48.9% vs 36.3%; P=.652). The Cox-regression 
did not identify variables associated with DFS and PFS. 
The IPI was the only prognostic variable for OS (IPI 
low/low intermediate risk vs high intermediate/high 
risk; hazard ratio=2.98; 95% CI: 1.01-8.77; P=.048).
Toxicities
There were significant differences in leukopenia grade 
4 (9% vs 18%; P=.031) and neutropenia grade 4 (13% 
vs 27%; P=.007). Febrile neutropenia was observed in 
3/92 (3%) A-CHOP cycles and 8/85 (9%) CHOP 
cycles (P=.131). There was no requirement for platelet 
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transfusions. Red blood cell transfusion was required in 
1 cycle of the A-CHOP group (1%) and in 4 cycles in the 
CHOP group (5%). Toxicity in 4/92 (4%) cycles led to 
hospitalization (median stay of 5 days) with A-CHOP 
and 11/85 cycles resulted in hospitalization (13%) with 
CHOP (median stay of 8 days, P=.05). Treatment de-
lays (more than 28 days between chemotherapies) were 
reported in 22/92 (24%) and 26/85 (31%) cycles in 
A-CHOP and CHOP respectively (P=.317) and the 
main causes were neutropenia and severe asthenia (simi-
lar incidence in both arms). The only long-term toxicity 
consisted of two cardiac events—a ventricular extrasys-
tole (A-CHOP arm) and an atrial fibrillation (CHOP 
arm).
DIsCussIon
Although the older population is growing, they are often 
excluded from clinical trials. Elderly patients are treated 
Table 1. patient and disease characteristics.
A-CHOP CHOP
P
No. % No. %
number of patients 18 16
Age (Years)
Median/range 74 (70-83) 73 (70-84) .881a
Sex
   Female 11 61 9 56
   Male 7 39 7 44 .774b
Disease localization
   nodal 15 83 14 88
   extranodal 3 17 2 13 .732b
Clinical stage
   i-ii 8 44 11 69
   iii-iV 10 56 5 31 .154b
International Prognostic Index
   Low-intermediate low 9 50 9 56
   intermediate high-high 9 50 7 44 .716b
Histology
   nHL dLbCL 14 78 12 75
   nHL peripheral T cell 1 6 1 6
   nHL mantle cell 2 11
   nHL malt high grade 1 6
   nHL  follicular center grade iii 1 6 1 6
   nHL unclassifiable 1 6
 Response
   Complete response 8 44 10 63 .535b
   partial response 8 44 3 19
   disease progression 1 6
   not evaluable 2 11 2 13
a:t-student; b:chi-square test
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Table 2.  Chemotherapy treatment exposure.
Cycle Ideal level
A-CHOP CHOP
P a
n Median n Median
Dose (mg/m2)
Cyclophosphamide
2nd 1500 17 1472b 16 1472b .35
4th 3000 15 2921b 14 2909b .39
6th 4500 11 4346b 12 4326b .46
doxorubicin
2nd 100 17 96.5b 16 96.4b .46
4th 200 15 190.5b 14 190.7b .46
6th 300 11 281.9b 12 285.9b .32
Relative dose intensity 
(%)
CHOp
2nd 100% 17 88%c 16 83%c .07
4th 100% 15 79%c 14 74%c .08
6th 100% 11 82%c 12 72%c .03
Treatment duration 
(weeks)
2nd 6 17 6.4d 16 7d .07
4th 12 15 13.6d 14 14.8d .07
6th 18 11 20.7d 12 22.9d .01
ap (1-tailed): Mann-Whitney U; bMedian dose in mg/m2; cMedian of percentage of ideal dose; dMedian of duration period in weeks.
with suboptimal doses of chemotherapy due to fear of 
toxicity and comorbidities. A previous study from our 
group shown that in patients older than 60 years (61-69 
vs ≥70 years old), there was no difference in the efficacy 
of chemotherapy, but there was in toxicity.1,6 
The standard CHOP dose improves survival in pa-
tients with malignant lymphomas and a 20% to 30% 
dose reduction is associated with lower complete re-
sponse rates and shorter OS. Although a relative dose 
intensity (RDI) ≥80% is a favorable factor for an in-
creased OS; these patients are 2.7 times more likely to 
experience a hospitalization due to febrile neutropenia.7 
Unfortunately, there are few studies evaluating RDI ef-
fect of CHOP in patients >70 years old. Pfreundschuh 
et al suggested a new standard regimen of chemotherapy 
with CHOP-14 and G-CSF in patients >60 years with 
an ideal RDI of 150; however only 20% of the patients 
included were >70 years old.8 In our study, the group 
receiving amifostine achieved a significantly higher RDI. 
Balducci et al evaluated nine studies in elderly pa-
tients with aggressive lymphoma and found that the risk 
of severe hematologic toxicity in patients >70 years was 
about 40%. The risk of developing septic neutropenia 
was 21% to 47%, and the risk of death from infection 
was 5% to 30%.9 In our study, grade 4 neutropenia was 
observed in 13% of A-CHOP cycles versus 27% in the 
control group. Likewise, febrile neutropenia was ob-
served in 3% of all cycles with amifostine versus 10% 
in the group without amifostine. Finally, there were no 
deaths related to chemotherapy, which is probably the 
result of the low observed RDI.9 Späth-Schwalbe et al 
evaluated amifostine plus CHOP in elderly patients 
with aggressive lymphoma. Patients over the age of 70 
received a total of 207 cycles with amifostine and, in a 
pattern similar to our results, they reported grade 4 leu-
kopenia in 15% of cycles, two cases of grade 3 anemias 
and febrile neutropenia in 4.3% of cycles, suggesting the 
efficacy of amifostine in reducing CHOP toxicity in el-
derly patients.5
Evaluating 177 cycles administered, we observed that 
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Table 3. Hematologic and non-hematologic toxicities.
A-CHOP
(92 Cycles)
CHOP
(85 cycles)
Events 1 2 3 4 1 2 3 4
Hematologic Toxicities
   anemia 23 3 25 7
   Leukopeniaa 9 25 42 9 8 22 40 18
   neutropeniaa 32 18 37 13 22 12 32 27
   Thrombocytopenia 23 1 22 4 1
Non hematologic 
toxicities
   emesis 8 1 1
   diarrhea 4 5 1
   Fatigue 2 1 5
   neuropathies 3
   elevated SgOT 12 1 5 2
   elevated SgpT   7 1 1 6 1
   elevated Creatinine 8 16 2
Values are percent. agrade 4: P=.031, bgrade 4: P= .007 
in >69 year-old NHL patients, CHOP plus amifostine 
was tolerated better than CHOP. A reduction in adverse 
events also reduced the number of hospitalizations dur-
ing the treatment without modify the long-term out-
come, but this should be studied with a larger sample 
size. We observed in both cohorts longer survivals than 
reported by Coffier et al (median OS of 3.5 years) for el-
derly patients treated with only CHOP.10 In conclusion, 
amifostine allows use of CHOP in a programed sched-
ule and prevents short-term toxicities without influenc-
ing statistically the treatment result in elderly patients 
with aggressive NHL treated with CHOP.
Author contributions
Data collection: HLG; FC; CSV; LV; LC; JL; FHM; 
CAC; JAP; data analysis: HLG; CF; JAP; manuscript 
preparation: all authors; manuscript approval: all authors.
Conflict of interest
The authors declared no conflict of interest.
original research reporta-CHOp in aggreSSiVe nHL
Hematol Oncol Stem Cell Ther 5(3)     Third Quarter 2012 hemoncstem.edmgr.com 157
1. gómez H, Hidalgo M, Casanova L, Colomer 
r, pen dL, Otero J, rodríguez W, Carracedo C, Cor-
tés-Funes H,Vallejos C. risk factors for treatment-
related death in elderly patients with aggressive 
non-Hodgkin’s lymphoma: results of a multivariate 
analysis. J Clin Oncol. 1998:2065-9.
2. Kourakis Mi. amifostine in clinical oncology: 
current use and future applications. anti-Cancer 
drugs 2002; 13:181-209.
3. Kemp g, rose p, Lurain J, berman M, Manetta 
a, roullet b, Homesley H, belpomme d, glick J. 
amifostine pretreatment for protection against 
cyclophosphamide-induced and cisplatin-induced 
toxicities: results of a randomized control trial in 
patients with advanced ovarian cancer. JCO 1996; 
14:2101-2112.
4. Lorusso d, Ferrandina g, greggi S, gadducci 
a, pignata S, Tateo S, biamonte r, Manzione L, di 
Vagno g,Ferrau’ F, Scambia g; Multicenter italian 
Trials in Ovarian Cancer invesitgators. phase iii 
multicenter randomized trial of amifostine as cy-
toprotectant in first-line chemotherapy in ovarian 
cancer patients. ann Oncol 2003; 14:1086-1093.
5. Späth-Schwalbe e, Lange C, genvresse i, Krüger 
L, eucker J, Schweigert M, Sezer O, budach 
V, possinger K influence of amifostine on toxicity 
of CHOp in elderly patients with aggressive non-
Hodgkin’s lymphoma-a phase ii study. anticancer 
drugs 2002; 13:395-403.
6. gómez H, Mas L, Casanova L, pen dL, Santil-
lana S, Valdivia S, Otero J, rodriguez W, Car-
racedo C, Vallejos C elderly patients with aggres-
sive non-Hodgkin’s lymphoma treated with CHOp 
chemotherapy plus granulocyte-macrophage 
colony-stimulating factor: identification of two age 
subgroups with differing hematologic toxicity. J 
Clin Oncol. 1998;16:2352-8.
7. Morrison Va, picozzi V, Scott S, pohlman 
b, dickman e, Lee M, Lawless g, Kerr r, Caggiano 
V, delgado d,Fridman M, Ford J, Carter Wb; On-
cology practice pattern Study Working group. 
Oncology practice pattern Study Working group. 
The impact of age on delivered dose intensity and 
Hospitalizations for Febrile neutropenia in patients 
with intermediate-grade non-Hodgkin’s Lympho-
ma receiving initial CHOp Chemotherapy: a risk 
Factor analysis. Clin Lymphoma 2001;2:47-56. 
8. pfreundschuh M, Trümper L, Kloess M, Schmits 
r, Feller aC, rübe C, rudolph C, reiser M, Hoss-
feld dK,eimermacher H, Hasenclever d, Schmitz 
n, Loeffler M; german High-grade non-Hodg-
kin’s Lymphoma Study group. german High-
grade non-Hodgkin’s Lymphoma Study group. 
Two/Weekly or 3-weekly CHOp chemotherapy 
with or without etoposide for the treatment of 
elderly patients with aggressive lymphomas: re-
sults of the nHL-b2 trial of the dSHnHL. blood 
2004;104:634-641.
9. balducci L, Lyman gH, Ozer H. patients aged > 
70 are at high risk for neutropenic infection and 
should receive hemopoitec grow factors when 
treated with moderately toxic chemotherapy. J 
Clin Oncol 2001;19:1583-1585.
10. Coiffier b, Thieblemont C, Van den neste 
e, Lepeu g, plantier i, Castaigne S, Lefort 
S, Marit g, Macro M,Sebban C, belhadj 
K, bordessoule d, Fermé C, Tilly H. Long-term 
outcome of patients in the LnH-98.5 trial, the first 
randomized study comparing rituximab-CHOp 
to standard CHOp chemotherapy in dLbCL pa-
tients: a study by the groupe d’etudes des Lym-
phomes de l’adulte. blood 2010 23;116:2040-5.
REFEREnCEs
